Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.00%104.101.1%$1332.57m
GILDGilead Sciences, Inc.
0.00%72.440.9%$675.30m
AMGNAmgen Inc.
0.00%170.001.1%$499.55m
BIIBBiogen Inc.
1.02%317.161.2%$472.85m
REGNRegeneron Pharmaceuticals, Inc.
0.00%391.592.7%$363.74m
ALXNAlexion Pharmaceuticals, Inc.
0.00%110.871.9%$288.55m
VRTXVertex Pharmaceuticals Incorporated
0.00%147.411.9%$237.28m
INCYIncyte Corporation
0.00%105.472.5%$187.59m
ALNYAlnylam Pharmaceuticals, Inc
0.00%127.5110.6%$184.43m
ILMNIllumina, Inc.
0.00%209.023.5%$165.18m
NKTRNektar Therapeutics
0.00%44.996.1%$146.11m
JUNOJuno Therapeutics, Inc.
0.00%58.6413.5%$138.44m
BMRNBioMarin Pharmaceutical Inc.
0.00%82.884.4%$117.68m
SRPTSarepta Therapeutics, Inc.
0.00%56.1116.8%$117.17m
BLUEBluebird Bio, Inc.
0.00%163.2017.2%$116.94m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.